Safety of three different product doses in autologous chondrocyte implantation: results of a prospective, randomised, controlled trial

Table 1 Study patients: demography and baseline characteristics (all patients)

Dose group Dose [spheroids/cm²]	Low	Medium	High	All patients
	3–7	10–30	40–70	All patients
	N = 25	N = 25	N = 25	N = 75
Sex
Female	8	4	10	22
Male	17	21	15	53
Age [years]	33 ± 10	34 ± 9	34 ± 9	34 ± 9
BMI
[kg/m²]	24.9 ± 2.5	25.6 ± 3.2	25.1 ± 3.6	25.2 ± 3.1
Range	21.3–29.8	19.4–33.2	19.0–32.3	19.0–33.2
Defect size
[cm²]	4.8 ± 1.5	4.9 ± 1.3	5.2 ± 1.3	5.0 ± 1.9
Range	0.5^a–7.5	1.3^a–7.5	3.0^a–8.0	0.5^a–8.0
Defect size group
4–6.99 cm²	22	22	21	65
7–10 cm²	3	3	4	10
Defect location (primary)
Femur	9	10	9	28
Tibia	–	–	–	–
Patella	16	15	16	47

Numbers of patients or mean ± SD, or where appropriate the range (minimum–maximum), are given
^aValue outside allowed range

ISSN: 1749-799X